Insulin therapy has proven benefits in Type 2 diabetes patients when combination therapy has failed. However, there is some reluctance by both patients and healthcare professionals to initiate insulin therapy. This reluctance has been termed 'psychological insulin resistance'. Barriers to the initiation of insulin therapy include patients' fear of disease progression and needle anxiety; mutual concerns about hypoglycaemia and weight gain; and health professionals' use of insulin as a threat to encourage compliance with earlier therapies. It is essential that these obstacles are identified and investigated as a means of overcoming these impediments to recommended levels of glycaemic control, an initiative being pursued by the DAWN study. Where concerns are tangible, such as fear of hypoglycaemia, therapeutic solutions can be pursued. Overcoming psychological barriers relies more on innovative management techniques. Improving insulin delivery to meet these needs, coupled with enhanced healthcare services, can address psychological insulin resistance and contribute to the maintenance of good metabolic control.
Introduction
A large percentage of individuals with Type 2 diabetes will eventually require exogenous insulin therapy to achieve and maintain recommended targets for glycaemic control. This is due at least in part to the progressive impairment in insulin secretion with ongoing beta-cell dysfunction, as was observed in the UKPDS. 1 Current strategies for treating Type 2 diabetes include the administration of a single oral agent when lifestyle intervention with diet and exercise regimens are not sufficient to maintain HbA 1C < 7% (with even lower targets now being considered). A second oral agent with an alternative mechanism of action is added when a single agent is not able to achieve or maintain optimal glycaemic control. With failure of combination therapy with two oral agents, the care provider is left with the decision of adding a third or fourth oral agent to the existing regimen, introducing an intermediate or long-acting insulin administered at bedtime, or changing to a basal=bolus insulin regimen.
Despite the demonstrated efficacy of insulin therapy in achieving and maintaining glycaemic control in people with Type 2 diabetes, there is both a spoken and unspoken reluctance from both physicians and patients to initiate this form of therapy. This reluctance to initiate insulin therapy in a timely manner contributes to prolonged periods of poor glycaemic control among individuals with Type 2 diabetes and ultimately increases the risk for neuropathic, microvascular and macrovascular complications. In one study, 2 30 -50% of patients with Type 2 diabetes categorized according to ethnic group (nonhispanic white, Hispanic and African American) did not even meet the minimal ADA recommendation of an HbA 1C < 8%, despite the fact that the majority (71 -83%) of these patients were receiving pharmacological hypoglycaemic therapy. This reluctance to initiate insulin therapy in a timely manner has been termed 'psychological insulin resistance' (PIR). PIR can interfere not only with initiation of insulin but also with attempts at intensifying insulin therapy in individuals already using insulin.
The purpose of this review is to address patient-and provider-related factors that contribute to PIR and to identify mechanisms by which these barriers can be overcome.
Barriers to insulin therapy

Patient factors
Factors contributing to PIR from the patient's point of view include fear of giving an injection, concern about preparing the correct dose of insulin, and fear of hypoglycaemia or weight gain (Table 1) . In one study, patients with Type 2 diabetes clearly understood the benefits of insulin but expressed concern regarding injection pain, proper injection technique, hypoglycaemia and the potential for health problems caused by insulin. 3 Zambanini et al studied 115 insulin-treated patients (80 Type 1 and 35 Type 2) who were questioned about anxiety with insulin injections and overall anxiety. 4 Of these patients, 28% had high injection anxiety scores; 45% admitted to avoiding injections, and 70% did not wish to take more than one or two injections per day.
Insulin therapy is perceived by many patients as more invasive and painful than diet and=or oral drug-based regimens. Berlin and colleagues found that increased intensity of phobic symptoms and anxiety-depression was associated with poor metabolic control. 5 Many patients may also express feelings of guilt and failure as they feel (or are made to feel) they have not adhered to diet and exercise regimens. They may be worried that the move to insulin means their disease is now much more serious. The finding that some physicians use insulin therapy as a threat to try to improve compliance with lifestyle interventions can contribute to this sense of failure on the part of many patients.
Some people find insulin injections inconvenient and embarrassing. 3 The timing of injections can be crucial, especially before meals. Current mealtime injections of soluble human insulin should ideally be given approximately 30 minutes before the meal. This time period is to allow plasma concentrations of insulin to increase to sufficient levels to control postprandial blood glucose excursions. Patients taking premeal insulin are often uncomfortable injecting themselves in public, and in the absence of a private area may either inject too early or in some cases omit an injection. Failure to coincide an injection with a meal can result in both hyperglycaemia and hypoglycaemia.
Healthcare provider factors
Factors contributing to PIR on the part of the physician or care provider may also include a sense of inadequacy or perceived inability to manage a patient's diabetes with treatments other than insulin. A lack of adequate time or personnel to instruct a patient on how to use insulin also serves as a barrier to its prescription. Together with the patient, a physician may also have concerns about hypoglycaemia and weight gain related to insulin therapy.
In one randomized study, approximately 45% of diabetologists were reluctant to start insulin treatment in patients due to patient refusal, fear of hypoglycaemia, or presence of a co-morbid condition that contributed to a reduced lifeexpectancy. 6 Highly insulin resistant patients An inability to achieve reductions in HbA 1C with insulin therapy has been suggested as another barrier to initiating or intensifying insulin therapy in patients with more severe degrees of insulin resistance, 7 who often require very high doses of insulin to achieve glycaemic control. 8 
Addressing PIR
Studies investigating structured healthcare projects have demonstrated a link between these identified barriers and a delay in initiation of insulin treatment. 9 An appreciation and understanding of both patient and physician barriers to insulin therapy can provide an important first step in overcoming these identified obstacles to achieving the mutually advantageous objective of optimal glycaemic control.
The DAWN study
There are few studies that have addressed the issue of psychosocial barriers to effective diabetes care. In a recent market research survey of 99 insulin-naïve diabetic patients in the UK and USA, 76% of patients expressed negative feelings about injecting and only 2% indicated that they would welcome insulin therapy. 10 To address this issue of PIR in a larger number of individuals with diabetes, the DAWN (Diabetes Attitudes Wishes and Needs) study, sponsored by Novo Nordisk, was initiated. The purpose of this study was to enhance the understanding of patient perceptions surrounding diabetes care and selfmanagement; as well as to develop insights into the attitudes Wirthlin Worldwide, a well-respected international market research company, was engaged to conduct the study. The format of DAWN included structured telephone or faceto-face interviews with diabetes patients, primary care physicians, specialists and nurses. Each interview lasted from 45 to 50 minutes. Questions asked were structured in order to explore the driving forces behind the effective self-management of diabetes (Figure 1 ).
More than 5000 people with diabetes and 3000 healthcare diabetes professionals in 13 countries (Australia, France, Germany, India, Japan, The Netherlands, Poland, Sweden, Norway, Denmark, Spain, UK and the USA) participated over a 5-month period (May to September 2001), making DAWN the largest global psychosocial diabetes study ever conducted.
Patient demographics. Early results of the DAWN study have been published. 11 In the US sample population, 17.7% were self-classified as having Type 1 diabetes, 37.2% as Type 2 using insulin, and 45.2% as Type 2 not using insulin. The proportions in other countries were 25.6%, 32.9% and 41.5%, respectively. The mean duration of diabetes varied from 9.1 to 29.4 y, depending on type of diabetes and country of origin. Of the Type 2 diabetes patients who were insulin users, 65.6% were on insulin at the time of the survey.
Interim results and implications. The DAWN study highlighted the importance of combining psychosocial support with appropriate medical care in achieving improved diabetes outcomes. Among all patients with diabetes, only 10% reported a feeling of 'good well-being' and one-third reported 'poor well-being'. Approximately half of patients felt stressed about their condition. Patients were found to take up to 16 months following diagnosis of Type 1 diabetes (8 months in Type 2 diabetes) to realise the chronic and serious nature of their condition. The most common reaction to diagnosis for both patient types was anxiety.
There were several areas identified that contributed to the large percentage of diabetes patients reporting poor wellbeing. Patient factors contributing to a poor sense of wellbeing included: anxiety about body weight (50% of patients); fear that their disease would worsen; fear of hypoglycaemic events; and fear among patients with Type 2 diabetes that they would eventually require insulin (50%) (Figure 2a) . However, the type of hypoglycaemic therapy used did not impact patient motivation to comply with diabetes treatment (Figure 2b) . 12 Patients throughout the world identified the importance of relationships with family, friends and colleagues as crucial factors in contributing to diabetes self-management practices and an overall sense of good well-being.
Of the healthcare professionals surveyed, fewer than half felt able to identify and evaluate patients' psychological needs, including their fears of worsening disease, fears of hypoglycaemia, weight concerns and stress. Currently used diabetes care protocols did not include evidence-based approaches to dealing with psychosocial issues surrounding diabetes management. Figure 2 The DAWN study.
12 a) More than half of all Type 2 patients not using insulin worry about having to start on insulin. b) Insulin does not impact upon patient motivation to comply with diabetes treatment.
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When asked their opinions on insulin initiation, 40% of healthcare professionals agreed that they 'prefer to delay the initiation of insulin until it is absolutely essential', with only 34% expressing a belief that 'earlier introduction of insulin would decrease the overall cost of diabetes in the long term'. In fact, 52% of specialists, 60% of primary care physicians, and 51% of nurses admitted to always or often cautioning patients that they would have to start on insulin therapy if they did not follow current prescribed hypoglycaemic regimens.
These interim data cast new light on the many psychological issues surrounding the management of diabetes and emphasize that these issues are not always perceived or addressed adequately by healthcare providers, generating further obstacles to insulin initiation and effective metabolic control. Using insulin therapy as a threat can reinforce myths and promote hostility in patients regarding initiation of insulin therapy.
Overcoming barriers to insulin initiation
Where concerns are clinical, such as fear of hypoglycaemia and ensuing cardiovascular disease, therapeutic solutions can be pursued. Overcoming psychological barriers relies more on innovative management and novel delivery techniques.
Prevention of hypoglycaemia
There will always be some risk of hypoglycaemia associated with diabetes management; however, this risk must be balanced against the greater risk of late diabetic complications and their impact on morbidity and mortality. Of interest in the DAWN study, despite an increased frequency of severe hypoglycaemic events, no major difference was observed in fear of hypoglycaemic events in Type 2 patients treated with insulin ( Figure 3 ). 12 Patients feel better when their blood glucose levels are under control. 13 While quality of life data from the UKPDS detected no adverse effect of hypoglycaemia on well-being, 14 the selection and use of an appropriate low dose insulin may reduce the effects of rapid normalization of glycaemia, and reduce the risk of hypoglycaemia during dose titration. 15 Studies of new insulin analogues, such as the rapid-acting insulin aspart, in Type 1 diabetes suggest that their use can improve postprandial control and glucose excursions in general, and at the same time reduce the likelihood of major hypoglycaemic episodes in comparison to traditional human insulin-based regimens. 16 -19 Risk of hypoglycaemia can be further managed by effective patient education regarding symptoms, treatment and peak times for insulin or oral agent action. Patients should also be encouraged to participate in home glucose monitoring and subsequent adjustments of their hypoglycaemic regimen.
Minimizing weight gain
Weight gain is often a major concern for many patients and since a high proportion of patients with Type 2 diabetes are overweight, issues of weight gain as a result of insulin therapy must be addressed.
Weight gain is commonly observed when pharmacological diabetes management is intensified. In most studies, when patients are provided with adequate initial advice and follow-up regarding lifestyle issues, weight gain with insulin therapy is modest. 20 The change in body weight is usually greatest during the early stages of therapy and then stabilizes. For example, patients receiving a twice-daily insulin regimen gained an average of 3.3 kg in the first 6 months of a long-term study, but only 1.3 kg in the second 6 months. 21 An increase in weight with insulin therapy is often attributed to the insulin, but may in fact be due to other factors, such as sedentary lifestyle or high fat diets that are observed in obese populations without diabetes. Up to 90% of patients with Type 2 diabetes are already overweight and further weight gain is probably inevitable in Type 2 diabetes when enthusiasm for diet or exercise programmes has waned. 22 A reduction in glucosuria associated with pharmacologically induced improvements in glycaemic control means retention of previously wasted calories and should prompt advice to decrease caloric consumption when insulin is introduced. Appropriate dietary advice and effective patient education throughout the course of Type 2 diabetes can help to control weight gain. 21 In addition to its effect on shortterm weight loss, an exercise programme may promote longterm weight loss with perseverance. 22 Exercise not only promotes weight loss, but also acts as an insulin sensitiser by activating glucose transporters within muscle, promoting the uptake of glucose.
The ADA's recommended diet is designed to limit the intake of fat to less than 30% of total calories, to eat regular meals as a way of distributing calories and glycaemic excursions over the course of a day, and to ensure adequate intake of fibre. In overweight individuals, a weight loss programme Figure 3 The DAWN study: little difference in fear of hypoglycaemic events was observed in Type 2 diabetes patients whether treated with insulin or not. 12 Overcoming barriers to insulin initiation M Korytkowski that seeks to achieve a loss of 5 -15% of current body weight can be useful in restoring euglycaemia. If hypoglycaemia occurs, it should be recommended that insulin dose is reduced rather than food intake increased.
Addressing risk for cardiovascular disease
There are several epidemiological studies that have established a link between the severity of hyperglycaemia and risk for cardiovascular disease. 23 -26 In the UKPDS, there was no acceleration in risk for atherosclerosis in those subjects randomised to insulin therapy at baseline. In those subjects assigned to intensive diabetes management with insulin, similar reductions in risk for myocardial infarction were observed with insulin therapy that approached significance (P ¼ 0.052).
Insulin may even reduce cardiovascular risk in people with Type 2 diabetes. 27 In a Swedish study, intensive insulin therapy was shown significantly to improve survival after myocardial infarction (MI) in hyperglycaemic patients. Patients (n ¼ 666) with a plasma glucose greater than 11 mmol=l (198 mg=dl) and suspected MI were randomized to routine care or to a protocol that included intravenous insulin and glucose for at least 24 hours, followed by four daily subcutaneous insulin injections for at least 3 months following hospitalization. The mortality reduction at 1 year was 30% (P ¼ 0.027), with the greatest decrease in mortality being observed among patients who were not receiving insulin at the time of admission. 28 Addressing needle anxiety The issue of needle anxiety is often underestimated. Recently, a specific self-testing questionnaire has been developed to assess the degree of anxiety towards needle injection in recognition of this problem. 29, 30 In patients who are already performing home glucose monitoring, reassurance that an insulin injection is less painful than a lancing device to obtain capillary blood for the test strip can help in part to alleviate needle anxiety. Having patients give themselves an injection with saline at the time of an office visit is another method of directly addressing anxieties regarding injection.
Research addressing needle phobias has largely focused on alleviating anxiety and pain by providing less traumatic methods of insulin delivery. An example is the insulin pen, an insulin delivery system designed to reduce the complexity of insulin dosing and minimize associated pain. A recent study found that pain perception was significantly less when using an insulin pen device (NovoPen 3, Novo Nordisk) than conventional syringes and vials. 31 The simplicity of insulin pen devices facilitates not only good glycaemic control, but also contributes to improved quality of life. 32 The development of finer, shorter needles has also helped to alleviate the pain of injections. In a recent study, needles with a smaller outer diameter caused significantly less pain than larger needles. 33 Non-visible needles are also associated with lower pain perception, as shown in a study using PenMate -an automatic injection device for use with the insulin pen NovoPen. 34 More recently, the FlexPen 1 , a new disposable device developed by Novo Nordisk, has been shown to be significantly preferable to users than NovoLet 1 , a prefilled insulin pen. 35 Users preferred the handling, ease of use and ease of dose setting of FlexPen 1 compared with NovoLet 1 . FlexPen 1 was also preferred by both patients and healthcare professionals in a comparative study with Humulin Pen (Eli Lilly) and Insuman Rapid OptiSet (Aventis Pharma). 36 Patient preference for particular pen devices was assessed in a multinational, multicentre study (n ¼ 137) in Type 2 diabetes using biphasic insulin aspart ( Overcoming barriers to insulin initiation M Korytkowski
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The future: psychological benefits of inhaled insulin A novel approach to the psychological barriers to insulin administration currently in development is inhaled insulin. Devices such as the AERx 1 iDMS system (Novo Nordisk, Aradigm Corp.) may soon provide a new inhaled treatment option for patients. Such devices would replace at least the need for meal-related insulin injections.
The efficacy of AERx 1 iDMS in Type 2 diabetes has already been established in a clinical proof of concept trial, 40 and Phase III studies are underway. Published reports already exist demonstrating the feasibility of inhaled insulin administered via less sophisticated inhalation devices than AERx 1 iDMS. For example, a small-scale, open-label, randomized trial demonstrated that, compared with subcutaneous insulin therapy, 41 ease of administration was significantly improved when using inhaled insulin. 40 There was also no significant difference in the metabolic control of patients on inhaled insulin compared with injected insulin.
In another study, inhaled insulin over three months significantly improved glycaemic control compared with baseline levels, although data from a comparator group receiving insulin injections were not published. 42 Further large-scale studies are needed to assess the relative efficacies of inhalation regimens as well as longterm glycaemic control. Nevertheless, inhalation may prove a less invasive alternative to injection therapy in Type 2 diabetes and help to overcome some of the psychological insulin resistance that exists surrounding needle therapy. Indeed, in a survey of 99 patients, 64% expressed a preference for inhaled insulin instead of injecting. 43 
Conclusions
There are many barriers to implementing insulin therapy in Type 2 diabetes patients for whom combination oral antidiabetic drug therapy has proven insufficiently effective. These barriers are erected by both patients and physicians. Elucidation of these obstacles and the reasons behind them can expose needs in diabetes management and assist in meeting them, as the DAWN study has shown. Improving insulin products and devices that overcome these barriers and enhancing healthcare services can together address psychological insulin resistance and contribute enormously to the maintenance of good metabolic control.
